Showing 2821-2830 of 5621 results for "".
- Millennial Demographics Drive Refractive Surgery Opportunity in UShttps://modernod.com/news/millennial-demographics-drive-refractive-surgery-opportunity-in-us/2479686/Wealth, health, and education are key factors in determining the opportunity for laser vision correction (LVC) procedures in the US, according to new Market Scope data. Refractive procedures are strongly driven by the country’s millennial population, and the high opportunity population is
- Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMDhttps://modernod.com/news/oxurion-and-beta-therapeutics-to-develop-new-heparanase-inhibitors-for-treatment-of-dry-amd/2479697/Oxurion announced that it entered into a strategic research collaboration with Beta Therapeutics (Canberra, Australia) to develop new heparanase inhibitors for the treatment of retinal disorders with large unmet medical needs such as dry age-related macular degeneration. Under the terms of
- $4 Million Gift to Aid Construction of a Public Museum Dedicated to Vision and Eye Healthhttps://modernod.com/news/aao-announces-4-million-gift-to-aid-construction-of-a-public-museum-dedicated-to-vision-and-eye-health/2479720/The American Academy of Ophthalmology announced a project to construct the world’s first public museum dedicated to vision and eye health. The new museum will be located in San Francisco. Prominent ophthalmologist Stanley M. Truhlsen, MD, launched the project with a $4 million donation. The annou
- EyePoint Pharmaceuticals Presents Positive Yutiq 24-month Follow-up Data at AAOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutuq-24-month-follow-up-data-at-aao/2479724/EyePoint Pharmaceuticals announced the presentation of 24-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Th
- Evidence Mounts That an Eye Scan May Detect Early Alzheimer’s Diseasehttps://modernod.com/news/evidence-mounts-that-an-eye-scan-may-detect-early-alzheimers-disease/2479725/Results from two studies show that a new, non-invasive imaging device can see signs of Alzheimer’s disease in a matter of seconds. The researchers show that the small blood vessels in the retina at the back of the eye are altered in patients with Alzheimer’s. Even patients who have a family histo
- Novartis: Two-Year Head-to-Head Data for Brolucizumab Reaffirm Superiority vs Aflibercept in Reducing Retinal Fluid in Patients With Wet AMDhttps://modernod.com/news/novartis-two-year-head-to-head-data-for-brolucizumab-reaffirm-superiority-vs-aflibercept-in-reducing-retinal-fluid-in-patients-with-wet-amd/2479727/Novartis announced additional brolucizumab phase 3 results from year 2 (96 weeks) that reaffirmed its positive year 1 (48 weeks) findings. Brolucizumab met its primary endpoint of noninferiority versus aflibercept in best corrected visual acuity (BCVA) and exhibited superiority in key retinal out
- Compact Imaging Collaborates with Novartis to Accelerate Development of Home Monitor for AMD and DRhttps://modernod.com/news/compact-imaging-collaborates-with-novartis-to-accelerate-development-of-home-monitor-for-amd-and-dr/2479735/Compact Imaging (CI), a developer of miniaturized optical coherence tomography (OCT) devices, announced the signing of a collaboration agreement with Novartis Pharma under which Novartis will fund Compact Imaging’s development of a low-cost home-based monitor to detect disease progression in adva
- LumiThera and Optos Announce Collaboration to Commercialize the Valeda Light Delivery System for Treating Dry AMD in Europehttps://modernod.com/news/lumithera-and-optos-announce-collaboration-to-commercialize-the-valeda-light-delivery-system-for-treating-dry-amd-in-europe/2479740/LumiThera announced a distribution agreement with Optos to exclusively distribute the Valeda Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in 12 European countries. The announcement follows the recent CE Mark certification for the European Union (EU) for th
- Foundation Fighting Blindness Launches Retinal Degeneration Fundhttps://modernod.com/news/foundation-fighting-blindness-launches-retinal-degeneration-fund/2479747/The Foundation Fighting Blindness announced the creation of the first Retinal Degeneration Fund (RD Fund), a wholly owned, 501(c)(3) not-for-profit subsidiary focused on making venture philanthropy investments to furt
- Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Diseasehttps://modernod.com/news/optos-and-amydis-establish-clinical-alliance-to-develop-early-diagnostic-test-for-alzheimers-disease/2479754/Optos, a subsidiary of Nikon Corporation, and Amydis announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ optomap ultra-wi